Navigation Links
Endocare and Former CFO Agree to Terminate Indemnification Agreement
Date:8/22/2008

IRVINE, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO) announced today that it has entered into an agreement with its former CFO, John V. Cracchiolo, pursuant to which Mr. Cracchiolo's indemnification agreement was terminated in exchange for Endocare's waiver of certain severance and legal fee reimbursement rights. For September 2008 through December 2008, the Company had budgeted over $875,000 for Mr. Cracchiolo's legal costs. As a result of this new agreement, the Company is no longer obligated to pay any future legal costs for Mr. Cracchiolo.

Please see the related Form 8-K filed by Endocare with the Securities and Exchange Commission this morning.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Investor Contact: Media Contact:

Matt Clawson Len Hall

Allen & Caron, Inc. Allen & Caron, Inc.

(949) 474-4300 (949) 474-4300

matt@allencaron.com len@allencaron.com

http://www.allencaron.com http://www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

http://www.endocare.com


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Endocare Comments on Unsolicited Proposal
2. Endocare Reports Financial Results for Second Quarter 2008
3. Endocare to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference
4. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
5. Endocare Announces That National Cancer Institute to Sponsor Study Comparing Cryoablation to Radiation Therapy for Pain Relief in Bone Cancer Patients
6. Endocare Reports 2007 Third Quarter and Nine-Month Results
7. Endocare Stock to Commence Trading on NASDAQ
8. Former U.S. Assistant Surgeon General, Dr. Susan Blumenthal, to Lead Meridian International Centers Global Health Program
9. Americas Agenda to Honor Former House Majority Leader Richard Gephardt at Democratic National Convention
10. Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey
11. Navilyst Medical Announces Global Debut Today : Former Boston Scientific Business Units Combine to Lead Fluid Management and Vascular Access Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Dental365 in Levittown opened just a few ... dentistry. Dental365 was established with the patient’s comfort and convenience in mind. ... high-quality, affordable dentistry while offering routine and walk-in emergency dental care 365 days a ...
(Date:5/4/2016)... ... May 05, 2016 , ... “Less than 15% of organizations nationwide can ... “As one of ten non-profit organizations to participate and complete the training, we are ... benefit is that for every $1 we invest in volunteer engagement, we can expect ...
(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the SOCKIT ... trainers to St. Jude Children’s Research Hospital to benefit families dealing with cancer ... designed to teach children how to kick a soccer ball correctly. The device ...
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP ... conference opened on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan ... a deep dive on NCPDP’s model solution to help stem the tide of ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... esteemed Quaker Ridge Golf Club in Scarsdale, New York on May 23, 2016 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology: